Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential.

Publications show all

Unum Therapeutics has published 2 articles.

SEC Filings show all

D2

SEC Form D Funding Events

DateOfferedSoldType
2014-10-20$12,252,685$6,252,685Equity

Key Executives

  • Charles Wilson
    Executive Officer, Director
  • Ben Auspitz
    Director
  • Bruce Booth
    Director